A Canadian real-world study reveals high oral corticosteroid exposure in patients with severe chronic rhinosinusitis with ...

Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

Please provide your email address to receive an email when new articles are posted on . Three currently available type 2 biologics approved for asthma appeared effective in treating chronic ...

GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...

SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prevalence of type 2 inflammation ranged from 64.2% to ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

Competition among biologics that target inflammatory respiratory disease is heating up even further. On Thursday, AstraZeneca said its Fasenra, used in tandem with standard steroids, significantly ...